14 active not recruiting. 14 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 14 |
| Phase 1 | 6 | Active not recruiting 6 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2025-11-06 | 2026-04-07 |
| Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-10-24 | 2026-07-13 |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-05-13 | 2026-08-13 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 5 | 2024-05-09 | 2026-06-08 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-03-14 | 2026-09-30 |
| Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy Cannabidiol oral solution - Epilepsy, Rare Diseases | Phase 2 | Active not recruiting | Meyer Children's Hospital IRCCS | 30 | 2024-03-14 | 2026-10-09 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 4 | 2024-02-28 | 2025-11-14 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-02-21 | 2026-04-09 |
| A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses - SCN2A-DEE, Epilepsy | Phase 1 / Phase 2 | Active not recruiting | Praxis Precision Medicines | 60 | 2023-04-13 | 2026-08-03 |
| RNS System LGS Feasibility Study RNS System - Epilepsy, Lennox Gastaut Syndrome | Phase 2 | Active not recruiting | NeuroPace | 24 | 2022-10-04 | 2026-09-15 |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Sirolimus, Placebo - Tuberous Sclerosis Complex, Epilepsy | Phase 2 | Active not recruiting | Darcy Krueger | 64 | 2021-10-13 | 2026-10-29 |
| An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome zorevunersen (STK-001) - Dravet Syndrome | Phase 2 | Active not recruiting | Stoke Therapeutics, Inc | 60 | 2021-01-20 | 2026-02-04 |
| A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy Perampanel Oral Suspension, Perampanel Tablet - Pediatric Epileptic Syndrome, Partial-onset Seizures | Phase 2 | Active not recruiting | Eisai Inc. | 100 | 2019-05-31 | 2026-07-10 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy XEN1101 - Focal Epilepsy | Phase 2 | Active not recruiting | Xenon Pharmaceuticals Inc. | 325 | 2019-01-30 | 2024-09-24 |
Seizures (4) · Drug Resistant Epilepsy (3) · Epilepsies, Myoclonic (3) · Epilepsies, Partial (3) · Myoclonic Epilepsies, Progressive (3) · Generalized Epilepsy With Febrile Seizures Plus, Type 2 (1) · Lennox Gastaut Syndrome (1) · Rare Diseases (1) · Tuberous Sclerosis (1)
Brain Diseases (14) · Central Nervous System Diseases (14) · Nervous System Diseases (14) · Epileptic Syndromes (7) · Epilepsy, Generalized (6) · Pathological Conditions, Signs and Symptoms (5) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Epilepsies, Myoclonic (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Congenital Abnormalities (1) · Disease Attributes (1) · Hamartoma (1)
Cannabidiol (1) · Sirolimus (1) · XEN1101 (1) · perampanel (1)
n-Lorem Foundation (3) · Biohaven Therapeutics Ltd. (2) · Encoded Therapeutics (2) · Darcy Krueger (1) · Eisai Inc. (1) · Meyer Children's Hospital IRCCS (1) · NeuroPace (1) · Praxis Precision Medicines (1) · Stoke Therapeutics, Inc (1) · Xenon Pharmaceuticals Inc. (1)
United States (11) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Czechia (2) · France (2) · Hungary (2) · Poland (2) · Argentina (1) · Austria (1) · Brazil (1) · Canada (1)
Ann Dandurand, MD (1) · Darcy A Krueger, MD, PhD (1) · Martha Morrell, MD (1) · Martina Bebin, MD, MPA (1) · Salvador Rico, M.D., Ph. D (1) · Salvador Rico, M.D., Ph.D (1)
PMID 37812429, PMID 41780062, PMID 42663529
2018 (2), 2023 (2), UH3NS109557 (1)